drugset / Trial / NCT00193596
Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
Phase 3
Completed
198 enrolled
SCRI Development Innovations, LLC
AstraZeneca · collabEli Lilly and Company · collabPharmacia and Upjohn · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
In this randomized trial, we will investigate the activity and toxicity of two active regimens, gemcitabine/irinotecan and paclitaxel/carboplatin/Etoposide (both followed by ZD1839) in the first-line treatment of patients with carcinoma of unknown primary site.
Timeline
- Start
- 2003-09
- Primary completion
- 2008-09
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 6 unknown | Intravenous |
| Subject | Etoposide | Small molecule | 50 mg | Oral |
| Subject | Etoposide | Small molecule | 100 mg | Oral |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 200 mg/m2 | Intravenous |